Nicotine Addiction - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Nicotine Addiction - Pipeline Review, H2 2018’, provides an overview of the Nicotine Addiction pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Nicotine Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Nicotine Addiction and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Nicotine Addiction

- The report reviews pipeline therapeutics for Nicotine Addiction by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Nicotine Addiction therapeutics and enlists all their major and minor projects

- The report assesses Nicotine Addiction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Nicotine Addiction

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Nicotine Addiction

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Nicotine Addiction pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Addex Therapeutics Ltd

Chronos Therapeutics Ltd

CV Sciences Inc

Heptares Therapeutics Ltd

Indivior Plc

Omeros Corp

Addex Therapeutics Ltd

Chronos Therapeutics Ltd

CV Sciences Inc

Heptares Therapeutics Ltd

Indivior Plc

Omeros Corp

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Nicotine Addiction – Overview

Nicotine Addiction – Therapeutics Development

Pipeline Overview

Pipeline ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Nicotine Addiction – Overview

Nicotine Addiction – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Nicotine Addiction – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Nicotine Addiction – Companies Involved in Therapeutics Development

Addex Therapeutics Ltd

Chronos Therapeutics Ltd

CV Sciences Inc

Heptares Therapeutics Ltd

Indivior Plc

Omeros Corp

Nicotine Addiction – Drug Profiles

(cannabidiol + nicotine) – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

18-MC – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ADX-71441 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AM-4113 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AM-6527 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AP-202 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AT-1001 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATI-3009 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C-4X3256 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CTDP-002 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EORA-101 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies for Nicotine Addiction – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Noribogaine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OMS-405 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OMS-527 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

psilocybin – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SBP-0069330 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Nicotine Addiction – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Alpha-4 Beta-2 Nicotinic Acetylcholine Receptor for CNS Disorders – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize CHRNA4 and CHRNB2 for Nicotine Addiction – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Dopamine, Serotonin, Norepinephrine Transporters for Central Nervous System Disorders – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Mollecules to Antagonize HCRTR1 for Addiction – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

URB-694 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Nicotine Addiction – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Nicotine Addiction – Dormant Projects

Nicotine Addiction – Discontinued Products

Nicotine Addiction – Product Development Milestones

Featured News & Press Releases

Jul 20, 2017: CV Sciences Cites Recent Clinical Study on Pharmaceutical-Grade CBD Shown to Lower Blood Pressure

Jul 11, 2017: CV Sciences Appoints Dr. Amy M. McCord as Director of Drug Development

Jun 19, 2017: CV Sciences Announces Commencement of IND preparation immediately following Pre-IND Meeting With FDA

May 02, 2017: CV Sciences Announces Pre-IND Meeting Date with FDA

May 20, 2015: Selection of drug candidate from Orexin-1 programme to treat stress-related addictive disorders and entry into pre-clinical development

Jul 10, 2014: Addex ADX71441 Positive Results in Preclinical Model of Nicotine Addiction

Mar 19, 2013: Omeros Elucidates Mechanism Of PDE7 Inhibitors In Addiction

Feb 16, 2012: Molecular Express announces award of STTR Phase I funding from the National Institutes of Health to develop a liposomal nicotine vaccine

May 05, 2011: Omeros Announces Expansion Of Potential Indications For PDE7 Inhibitors

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Nicotine Addiction, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products ...

List of Tables

Number of Products under Development for Nicotine Addiction, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Nicotine Addiction – Pipeline by Addex Therapeutics Ltd, H2 2018

Nicotine Addiction – Pipeline by Chronos Therapeutics Ltd, H2 2018

Nicotine Addiction – Pipeline by CV Sciences Inc, H2 2018

Nicotine Addiction – Pipeline by Heptares Therapeutics Ltd, H2 2018

Nicotine Addiction – Pipeline by Indivior Plc, H2 2018

Nicotine Addiction – Pipeline by Omeros Corp, H2 2018

Nicotine Addiction – Dormant Projects, H2 2018

Nicotine Addiction – Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Nicotine Addiction, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products ...

List of Figures

Number of Products under Development for Nicotine Addiction, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports